Followers | 840 |
Posts | 121733 |
Boards Moderated | 10 |
Alias Born | 09/05/2002 |

Wednesday, August 03, 2022 11:59:54 AM
https://www.businesswire.com/news/home/20220803005334/en
Merck…today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRK News
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 02:13:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (Canada) • 07/07/2025 02:01:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 02:01:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • InvestorsHub NewsWire • 07/07/2025 01:00:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 12:30:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (US) • 07/07/2025 12:30:00 PM
- Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • PR Newswire (Canada) • 07/07/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 04:08:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 04:06:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 04:04:07 PM
- FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial • Business Wire • 07/02/2025 10:45:00 AM
- Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29 • Business Wire • 07/01/2025 10:45:00 AM
- Gilead Advances After Supreme Court Backs Preventive Care Coverage Under ACA • IH Market News • 06/30/2025 12:53:42 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/27/2025 06:16:51 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/27/2025 06:12:30 PM
- Form 11-K - Annual report of employee stock purchase, savings and similar plans • Edgar (US Regulatory) • 06/27/2025 06:08:51 PM
- ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season • Business Wire • 06/26/2025 05:39:00 PM
- Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention • Business Wire • 06/24/2025 10:45:00 AM
- Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH) • Business Wire • 06/23/2025 10:45:00 AM
- IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer • Business Wire • 06/18/2025 11:00:00 AM
- FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent • Business Wire • 06/13/2025 10:45:00 AM
- Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs • Business Wire • 06/12/2025 08:45:00 PM
- Merck Launches Final-Stage Trial of Dengue Vaccine for Children • IH Market News • 06/12/2025 01:51:02 PM
- Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate • Business Wire • 06/12/2025 10:45:00 AM
- U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season • Business Wire • 06/09/2025 07:11:00 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM
One World Products, Inc. Appoints William Rowland as Chief Financial Officer • OWPC • Jul 1, 2025 9:14 AM
Envirotech Begins Delivery of Bumble Bee Electric School Bus Units with First Three Texas Orders • EVTV • Jul 1, 2025 9:01 AM